Tandem Diabetes Care (Nasdaq:TNDM), based in San Diego, has been actively developing its automated insulin delivery systems over the past couple of years. The company offers two distinct pump platforms: the flagship t:slim X2 and the newer Mobi miniature durable pump. Both feature advanced software and connectivity to leading continuous glucose monitors (CGMs).
The company’s product line continues to evolve with new integrations, updated infusion technology, and enhancements to its automated insulin delivery platforms. These updates cater to a growing range of people with diabetes. A significant driver for Tandem is its new Control-IQ+ technology, which is improving its pump systems. At the American Diabetes Association’s 85th Scientific Sessions, Ben Mar, Tandem’s Director of Product Marketing, discussed the company’s goal of providing options for diabetes management.
The company’s commitment to innovation is evident in its ongoing developments. By expanding compatibility with updated CGM sensors and improving infusion technology, Tandem is broadening its offerings. The enhancements to its automated insulin delivery systems demonstrate the company’s focus on addressing the diverse needs of people with diabetes.
